Anti-NGF antibodies for the therapeutic treatments

Details Anti-NGF antibodies for the therapeutic treatments Anti-NGF antibodies for the therapeutic treatments

2002-05-09

2010-06-01

Belyavskyi, Michail A (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S142100

Reexamination Certificate

active

07727527

ABSTRACT:
The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.

REFERENCES:
patent: 4906476 (1990-03-01), Radhakrishnan
patent: 5470578 (1995-11-01), Aoki et al.
patent: 7425329 (2008-09-01), Shelton et al.
patent: 2001/0046959 (2001-11-01), Buchkovich et al.
patent: 2004/0131615 (2004-07-01), Shelton et al.
patent: 2004/0253244 (2004-12-01), Shelton et al.
patent: 2006/0147450 (2006-07-01), Shelton
patent: 2009/0252744 (2009-10-01), Shelton et al.
patent: WO 00/73344 (1988-09-01), None
patent: WO 01/78698 (2001-10-01), None
patent: WO 0178698 (2001-10-01), None
Feldman et al., Transplant. Proc. 1998, 30, 4126-4127.
Mestas et at J. of Immunology, 2004, 172, pp. 2731-238.
Van Noort et al. International Review of Cytology, 1998).
Ro et al Pain, 1999, v.79, pp. 265-274.
Braun et al., E J. Immunol, 1998, v.28, pp. 3240-3251.
Owens et al 1994 v.168, pp. 149-165.
Shih et al., “Mutagenesis Identifies Amino-Terminal Residues of Nerve Growth Factor Necessart for Trk Receptor Binding and Biological Activity”, The Journal of Biological Chemistry, vol. 269, No. 44, pp. 27679-27686 (1994) XP002062137, ISS: 0272-457X.
Torcia et al., “Nerve Growth Factor is an Autocrine Survival Factor for Memory B Lymphocytes”, Cell, vol. 85, pp. 345-356 (1996), XP001153068, ISSN: 0092-8674.
Hongo et al., “Antibody Binding Regions on Human Nerve Growth Factor Identified by Homolog- and Alanine-Scanning Mutagenesis”, Hybridoma, vol. 19, No. 3, pp. 215-227, 2000 (XP-002951932).
Shih et al., “Mutagenesis Identifies Amino-terminal Residues of Nerve Growth Factor Necessary for Trk Receptor Binding and Biological Activity”, The Journal of Biological Chemistry, vol. 269, No. 44, Issue of Nov. 4, pp. 27679-27686, 1994 (XP-002062137).
Torcia et al., “Nerve Growth Factor Is an Autocrine Survival Factor for Memory B Lymphocytes”, Cell, vol. 85, pp. 345.346, May 3, 1996 (XP-001153068).
Morrison, S. et al., “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains”, Proc. Natl. Acad. Sci. USA, vol. 81, pp. 6851-6855 (1984).
Holliger, P. et al., ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 6444-6448 (1993).
Braun et al., “Role of Nerve Growth factor in a Mouse Model of Allergic Airway Inflammation and Asthma” Eur. J. Immunol. 1998, 28:3240-3251.
Braun et al., “Neurotrophins: A Link Between Airway Inflammation and Airway Smooth Muscle Contractility in Asthma?” Int. Arch Allergy Immunol. 1999;118;163-065.
Garaci et al. “Nerve Growth Factor is an autocrine factor essential for the survival of macrophages infected with HIV”Proc. Natl. Acad. Sci. 96(24):14013-14018 (1999).

Affiliated with

Also associated with

Rating

Anti-NGF antibodies for the therapeutic treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-NGF antibodies for the therapeutic treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-NGF antibodies for the therapeutic treatments will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4154128